Healthcare providers across Europe are taking a cautious approach towards the process, according to medical aid organisation the National Association of Councils for the Care of the Elderly (NCCE).
“In the most recent NEPA Report for Carer Information, usage of the service is low, and the decline in usage is showing little sign of slowing down,” said NCCE in a report.
That state of affairs is likely to extend into 2019.
In 2010, the EU Council of Ministers made obligatory the re-seeding of social care by-products, such as corticosteroids or neutraceuticals.
Many health practitioners are anxious about an influx of patients who are allergic to corticosteroids in the midst of a genuine flare-up, and who are unlikely to be up to taking medication for the rest of their lives.
And the issue of guaranteeing that people are put in the right environments with the correct treatment has proved far more complex than initially anticipated.
Currently, patients have to prove that they are allergic to the substances to begin the process of re-seeding the pharmacy shelf.
But people with asthma and allergies to mucus allergies – and to an earlier point, to exposure to exercise and air pollutants – already have access to the appropriate healthcare professionals.
Access to treatments is protected by the Health and Social Care Act and by an agreement between the European Commission and the member states.
An open letter to ministers from the UK, signed by some 26 doctors’ leaders in UK primary care earlier this year, has raised concerns about the lack of information on re-seeding guidelines for a lack of clarity on how to access and use the service.
This is despite the MoHS reform legislation having approved funds for re-seeding of minor substances back in 2015.
A spokeswoman for the UK National Health Service told BBC News in July that the targets on re-seeding of health conditions should be met by the end of this year.
As yet, no firm statement on this has been forthcoming.
There has also been no clear action on what to do about the neglect of staff through a reluctance to spend millions on the process.
Just 10 percent of UK NHS pharmacies are using the practice, largely due to concerns about the cost.
The charity Allergy UK has reported that there is now less than a quarter of a million people taking care of themselves at home instead of going to the emergency department for treatment.
The benefits of home-care are also being masked by the bigger picture of a lack of funding to support communities where services are required most, and by the lack of funds for nurse assessments or to help pharmacy staff to process all the prescriptions.
Nowhere are the forces affecting the UK’s health and social care system as apparent as in our homes.
The public sector watchdog the Care Quality Commission is currently investigating as many as 50 organisations in a round of inspections that it believes has cut and cut and cut – sometimes using inbreeding to save money – while poorly performing organisations continue to churn out dissatisfied patients.
Sick bed attendances are up across the NHS, and referral rates to accident and emergency units across England have increased by 25 per cent since 2013.
Meanwhile, funding for home care has more than halved since 2012.
All too often, we are told to plug that funding gap by ignoring the urgent need for these professionals – places where the lives of vulnerable patients and relatives could be immeasurably improved.